Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 427 of 5804
-
New combo therapy aims to tackle Hard-to-Treat lung cancer
Disease control Recruiting nowThis study is an open-label, randomized, controlled, multicenter Phase IIIb clinical study, aiming to evaluate the efficacy, safety, and tolerability of Vebreltinib Enteric Capsule combined with platinum-based doublet chemotherapy compared with platinum-based doublet chemotherapy…
Phase: PHASE3 • Sponsor: Beijing Pearl Biotechnology Limited Liability Company • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Gene therapy eye drops aim to heal corneas in rare nerve disorder
Disease control Recruiting nowThe Sponsor is developing KB801, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human nerve growth factor (NGF) to the corneas of people with Stage 2 or 3 neurotrophic keratitis (NK) via top…
Phase: PHASE1, PHASE2 • Sponsor: Krystal Biotech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New vaccines aim to block malaria transmission in africa
⭐️ VACCINE ⭐️ OngoingAssessing the safety, immunogenicity and ex-vivo efficacy of two transmission blocking vaccines (Pfs25-IMX313 in Matrix M and Pfs48/45 in Matrix M alone and co-administered) in Burkina Faso, in 18-45 years, 12-17 years and 05-11 year olds.
Phase: PHASE1, PHASE2 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:08 UTC
-
Triple threat before surgery: could this combo shrink lung tumors better?
Disease control Recruiting nowThis phase II study aims to evaluate the efficacy and safety of low-dose radiation + SBRT + Tislelizumab plus platinum-based chemotherapy as neoadjuvant therapy for stage II-III non-small cell lung cancer.
Phase: PHASE2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug INV-6452 targets Hard-to-Treat breast cancers
Disease control Recruiting nowThis is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-6452 in adult patients with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) advanced/metastatic breast ca…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo takes on Hard-to-Treat prostate cancer
Disease control Recruiting nowThe purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about: * The safety of the …
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Race against time: does immediate carotid surgery cut stroke risk?
Disease control Recruiting nowIn patients with internal carotid artery (ICA) stenosis of 50% or greater (measured according to the criteria of the North American Symptomatic Carotid Endarterectomy Trial (NASCET)) who have experienced a transient ischemic attack (TIA) or minor ipsilateral stroke, carotid endar…
Phase: NA • Sponsor: Italian Society of Vascular and Endovascular Surgery • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Can a higher dose of xolair beat food allergies?
Disease control Recruiting nowThis research is being conducted to assess the safety and effectiveness of increased dosing of Omalizumab for food allergies.
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Could a shot cure your acne? new mRNA vaccine trial begins
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of the VBE00009 study is to evaluate the safety, efficacy and immunogenicity of 2 administrations of the Acne mRNA vaccine candidate at single dose level in participants aged 18 to 45 years with mild acne. This study will consist of a Core Study followed by an optiona…
Phase: PHASE1, PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 11, 2026 00:00 UTC
-
New hope for tough prostate cancer: drug combo trial launches
Disease control OngoingThis Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with meta…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
VA launches program to bring precision cancer care to more veterans
Disease control Recruiting nowThe investigators are rolling out a 3 level intervention designed to improve the use of Precision Oncology at 8 VA medical centers. The 3 components of the intervention are 1: a short educational video for patients, 2: audit and feedback to providers on their Precision Oncology p…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New hope for rare blood disease: teclistamab trial targets AL amyloidosis
Disease control OngoingThis is a multicenter open-label, phase 2 study in participant with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the benefit of teclistamab
Phase: PHASE2 • Sponsor: European Myeloma Network B.V. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New COPD drug shows promise in cutting lung Flare-Ups
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.
Phase: PHASE2 • Sponsor: Upstream Bio Inc. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug tarlatamab takes on tough lung cancers
Disease control Recruiting nowUNLOCK TARLATAMAB is an open-label, single arm, multicenter, phase 2 platform study that aims to evaluate the mechanisms of action and resistance to tarlatamab in metastatic/locally advanced Small-Cell Lung Cancer (SCLC) with any level of DLL3 expression and in other poorly diffe…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control ENROLLING_BY_INVITATIONThis study will have two Phases: Phase 1a and Phase 1b. The goal of this clinical study is to learn more about the study drug KITE-363, to establish dosing, tolerability, safety, and preliminary efficacy of KITE-363 in participants with refractory autoimmune diseases. The primar…
Phase: PHASE1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for hard-to-treat myeloma: experimental combo tested in phase 2 trial
Disease control Recruiting nowThis is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma.
Phase: PHASE2 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Stem cells injected into spine: hope for paralysis?
Disease control Recruiting nowThis Phase I clinical trial is designed to evaluate the safety, tolerability of XS228 ( iPSC-Derived Motor Neuron Progenitor Cells) in patients with Subacute Spinal Cord Injury
Phase: PHASE1 • Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New rapid test could save lives of febrile children in africa
Diagnosis Recruiting nowThe overall aim of the study is to provide evidence that introducing novel biomarkers evaluation at triaging (first clinical assessment), in combination with IMCI-based guidelines (SoC), is a viable strategy to enhance rapid and accurate identification of febrile children at incr…
Phase: NA • Sponsor: Barcelona Institute for Global Health • Aim: Diagnosis
Last updated Jun 27, 2026 09:05 UTC
-
New drug duo offers hope for hard-to-treat head and neck cancer
Disease control Recruiting nowThe purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Brain-Wash breakthrough? new trial takes on deadly ventriculitis
Disease control Recruiting nowVentriculitis is a severe infectious disease of the central nervous system with diverse etiologies. Currently, the treatment for ventriculitis is challenging, with poor prognosis. The mortality rate of ventriculitis is generally reported to be higher than 30%, with the highest re…
Phase: NA • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC